{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040608","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.427597+00:00","generated_at":"2026-06-11T22:12:19.579578+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xenon reports Q2 net loss $47.5M; XEN1101 MDD trial fully enrolled with data expected late Nov-Dec","bullets":["Q2 net loss $47.5M vs $31.2M YoY; R&D expenses doubled to $44.0M on XEN1101 Phase 3 and MDD trials.","Cash $652.2M (down from $720.8M); sufficient to fund operations into 2026.","Last patient enrolled in XEN1101 Phase 2 X-NOVA MDD trial; topline data expected late Nov to mid-Dec 2023.","Phase 3 epilepsy trials X-TOLE2/3 and X-ACKT continue; partnered NBI-921352 Phase 2 data expected Q4 2023.","Webinar on MDD mechanism and X-NOVA design scheduled for mid-September."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040608","json":"https://secwatch.observer/filing/0000950170-23-040608.json","markdown":"https://secwatch.observer/filing/0000950170-23-040608.md","text":"https://secwatch.observer/filing/0000950170-23-040608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023040608/0000950170-23-040608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023040608/xene-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:12:19.579578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78a0ed7634347df359dd4820d2435ccab02aba5a","claim":"Xenon Pharmaceuticals Inc. reported financial results for three and six months ended June 30, 2023.","evidence_excerpt":"On August 9, 2023, Xenon Pharmaceuticals Inc. (the \"Company\") announced via press release the Company's financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023040608/0000950170-23-040608-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}